The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis

References

• Aquino CC, Fox SH. (2015). Clinical spectrum of levodopa-induced complications. Mov Disord 30:80–9.
   PubMed Web of Science ®Google Scholar
• Bara-Jimenez W, Dimitrova TD, Sherzai A, et al. (2006). Glutamate release inhibition ineffective in levodopa-induced motor complications. Mov Disord 21:1380–3.
   PubMed Web of Science ®Google Scholar
• Bellingham MC. (2011). A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther 17:4–31.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Ludolph A, Agid Y, et al. (2009). Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132:156–71.
   PubMed Web of Science ®Google Scholar
• Bonelli RM, Hofmann P. (2007). A systematic review of the treatment studies in Huntington’s disease since 1990. Expert Opin Pharmacother 8:141–53.
   PubMed Web of Science ®Google Scholar
• Braz CA, Borges V, Ferraz HB. (2004). Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clin Neuropharmacol 27:25–9.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670–83.
   PubMed Web of Science ®Google Scholar
• Coppen EM, Roos RA. (2017). Current pharmacological approaches to reduce chorea in Huntington's disease. Drugs 7:29–46.
   Web of Science ®Google Scholar
• Corcia P, Meininger V. (2008). Management of amyotrophic lateral sclerosis. Drugs 68:1037–48.
   PubMed Web of Science ®Google Scholar
• de Bartolomeis A, Errico F, Aceto G, et al. (2015). D-aspartate dysregulation in Ddo(-/-) mice modulates phencyclidine-induced gene expression changes of postsynaptic density molecules in cortex and striatum. Prog Neuropsychopharmacol Biol Psychiatry 62:35–43.
   PubMed Web of Science ®Google Scholar
• Dickson DW. (2012). Parkinson’s disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med 2:a009258.
   PubMed Web of Science ®Google Scholar
• Douhou A, Debeir T, Murer MG, et al. (2002). Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice. Exp Neurol 176:247–53.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S (editors). (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org
   Google Scholar
• Huntington Study Group. (2003). Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 61:1551–6.
   PubMed Web of Science ®Google Scholar
• Jankovic J. (2016). Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother 17:2461–70.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Hunter C. (2002). A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 8:271–6.
   PubMed Web of Science ®Google Scholar
• Jenkins TM, Hollinger H, McDermott CJ. (2014). The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Curr Opin Neurol 27:524–31.
   PubMed Web of Science ®Google Scholar
• Katsuno M, Watanabe H, Yamamoto M, et al. (2014). Potential therapeutic targets in polyglutamine-mediated diseases. Expert Rev Neurother 14:1215–28.
   PubMed Web of Science ®Google Scholar
• Landwehrmeyer GB, Dubois B, de Yébenes JG, et al. (2007). Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 62:262–72.
   PubMed Web of Science ®Google Scholar
• Liu J, Bader B, Danek A. (2014). Neuroacanthocytosis in china: a review of published reports. Tremor Other Hyperkinet Mov (NY) 4:248.
   PubMedGoogle Scholar
• Liu J, Wang LN. (2014). Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone. CNS Drugs 28:63–8.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang LN. (2017). Hyperkinesia in ancient China: perspectives and prescriptions. CNS Spectr 22:251–3.
   PubMed Web of Science ®Google Scholar
• Merims D, Ziv I, Djaldetti R, et al. (1999). Riluzole for levodopa-induced dyskinesias in advanced Parkinson’s disease. Lancet 353:1764–5.
   PubMed Web of Science ®Google Scholar
• Oertel W, Schulz JB. (2016). Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem 139:325–37.
   PubMed Web of Science ®Google Scholar
• Ristori G, Romano S, Visconti A, et al. (2010). Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 74:839–45.
   PubMed Web of Science ®Google Scholar
• Romano S, Coarelli G, Marcotulli C, et al. (2015). Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 14:985–91.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Olanow CW, Greenamyre JT, et al. (2014). Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: future therapeutic perspectives. Lancet 384:545–55.
   PubMed Web of Science ®Google Scholar
• Scherfler C, Sather T, Diguet E, et al. (2005). Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (Parkinson variant of multiple system atrophy). J Neural Transm 112:1025–33.
   PubMed Web of Science ®Google Scholar
• Schiefer J, Landwehrmeyer GB, Lüesse HG, et al. (2002). Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington’s disease. Mov Disord 17:748–57.
   PubMed Web of Science ®Google Scholar
• Seppi K, Peralta C, Diem-Zangerl A, et al. (2006). Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol 13:1146–8.
   PubMed Web of Science ®Google Scholar
• Squitieri F, Orobello S, Cannella M, et al. (2009). Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging 36:1113–20.
   PubMed Web of Science ®Google Scholar
• Tsou AY, Friedman LS, Wilson RB, et al. (2009). Pharmacotherapy for Friedreich ataxia. CNS Drugs 23:21323.
   PubMed Web of Science ®Google Scholar